Kristian Tonby

List of Publications by Year
in descending order

27 papers	1,221 citations	516710 16 h-index	526287 27 g-index
30 all docs	30 docs citations	30 times ranked	2461 citing authors

#	Article	IF	Citations
1	Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 25018-25025.	7.1	279
2	Dyspnoea, lung function and CT findings 3â€¦months after hospital admission for COVID-19. European Respiratory Journal, 2021, 57, 2003448.	6.7	243
3	Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19. Annals of Internal Medicine, 2021, 174, 1261-1269.	3.9	84
4	IP-10 differentiates between active and latent tuberculosis irrespective of HIV status and declines during therapy. Journal of Infection, 2015, 70, 381-391.	3.3	76
5	Increased interleukin-6 and macrophage chemoattractant protein-1 are associated with respiratory failure in COVID-19. Scientific Reports, 2020, 10, 21697.	3.3	65
6	Blood neurofilament light concentration at admittance: a potential prognostic marker in COVID-19. Journal of Neurology, 2021, 268, 3574-3583.	3.6	56
7	Detailed stratified GWAS analysis for severe COVID-19 in four European populations. Human Molecular Genetics, 2022, 31, 3945-3966.	2.9	46
8	IP-10 measured by Dry Plasma Spots as biomarker for therapy responses in Mycobacterium Tuberculosis infection. Scientific Reports, 2015, 5, 9223.	3.3	45
9	Respiratory dysfunction three months after severe COVIDâ€19 is associated with gut microbiota alterations. Journal of Internal Medicine, 2022, 291, 801-812.	6.0	38
10	A Phase I/II randomized trial of H56:IC31 vaccination and adjunctive cyclooxygenase-2-inhibitor treatment in tuberculosis patients. Nature Communications, 2021, 12, 6774.	12.8	34
11	Cyclooxygenase inhibitors impair CD4 T cell immunity and exacerbate Mycobacterium tuberculosis infection in aerosol-challenged mice. Communications Biology, 2019, 2, 288.	4.4	31
12	Elevated plasma sTIM-3 levels in patients with severe COVID-19. Journal of Allergy and Clinical Immunology, 2021, 147, 92-98.	2.9	31
13	The COX- inhibitor indomethacin reduces Th1 effector and T regulatory cells in vitro in Mycobacterium tuberculosis infection. BMC Infectious Diseases, 2016, 16, 599.	2.9	29
14	Predicting severe COVID-19 in the Emergency Department. Resuscitation Plus, 2020, 4, 100042.	1.7	23
15	A Plasma 5-Marker Host Biosignature Identifies Tuberculosis in High and Low Endemic Countries. Frontiers in Immunology, 2021, 12, 608846.	4.8	21
16	Critical COVIDâ€19 is associated with distinct leukocyte phenotypes and transcriptome patterns. Journal of Internal Medicine, 2021, 290, 677-692.	6.0	20
17	Elevated Levels of Anti-Inflammatory Eicosanoids and Monocyte Heterogeneity in Mycobacterium tuberculosis Infection and Disease. Frontiers in Immunology, 2020, 11, 579849.	4.8	18
18	Targeting Tuberculosis and HIV Infection-Specific Regulatory T Cells with MEK/ERK Signaling Pathway Inhibitors. PLoS ONE, 2015, 10, e0141903.	2.5	18

#	Article	IF	Citations
19	Monocytic myeloid-derived suppressor cells reflect tuberculosis severity and are influenced by cyclooxygenase-2 inhibitors. Journal of Leukocyte Biology, 2021, 110, 177-186.	3.3	13
20	Delirium is common in patients hospitalized with COVID-19. Internal and Emergency Medicine, 2021, 16, 1997-2000.	2.0	9
21	Neutrophil count predicts clinical outcome in hospitalized COVID‑19 patients: Results from the NOR‑Solidarity trial. Journal of Internal Medicine, 2022, 291, 241-243.	6.0	9
22	Serum ACE as a prognostic biomarker in COVID‑19: a case series. Apmis, 2021, 129, 237-238.	2.0	6
23	Low prevalence of positive interferon-gamma tests in HIV-positive long-term immigrants in Norway. International Journal of Tuberculosis and Lung Disease, 2014, 18, 180-187.	1.2	5
24	CCL1 and IL-2Ra differentiate Tuberculosis disease from latent infection Irrespective of HIV infection in low TB burden countries. Journal of Infection, 2021, 83, 433-443.	3.3	4
25	Plasma LOX-Products and Monocyte Signaling Is Reduced by Adjunctive Cyclooxygenase-2 Inhibitor in a Phase I Clinical Trial of Tuberculosis Patients. Frontiers in Cellular and Infection Microbiology, 2021, 11, 669623.	3.9	3
26	Regional performance variation in external validation of four prediction models for severity of COVID-19 at hospital admission: An observational multi-centre cohort study. PLoS ONE, 2021, 16, e0255748.	2.5	3
27	KLRG1-Expressing CD4 T Cells Are Reduced in Tuberculosis Patients Compared to Healthy Mycobacterium tuberculosis‑Infected Subjects, but Increase With Treatment. Journal of Infectious Diseases, 2019, 220, 174-176.	4.0	2